Source: Lumos Diagnostics
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Lumos Diagnostics (LDX) receives authorisation to sell its COVID-19 rapid diagnostic test in Canada
  • CoviDx gives healthcare providers results within 15 to 20 minutes, with a simple ‘yes or no’ answer
  • The test will be available to qualified healthcare providers in Canada through Lumos’ Canadian distribution partners
  • Lumos says the authorisation helps advance public health and safety in Canada and supports the continuity of commerce, tourism and education across the country
  • On the market this afternoon, Lumos is up a slight 0.85 per cent to trade at 86 cents

Lumos Diagnostics (LDX) has received authorisation to sell and distribute its COVID-19 rapid test in Canada.

CoviDx is a point-of-care diagnostic test that uses individual pre-filled extraction reagent vials to make it easy to administer in any patient care setting. It also provides a simple ‘yes/no’ result.

CoviDx gives healthcare providers results within 15 to 20 minutes in cases of suspected COVID-19 or performing serial testing in patients without symptoms.

The test will be available to qualified healthcare providers in Canada through Lumos’ Canadian distribution partners.

Lumos CEO and President Rob Sambursky spoke on the authorisation in Canada.

“As SARS-CoV-2 continues to evolve, rapid point-of-care testing is a critical component of the Canadian public health response”, he said.

“Using CoviDx as part of routine testing and triage protocols can help advance public health and safety in Canada, while also supporting the important efforts underway to ensure the continuity of commerce, tourism and education across the country.”

On the market this afternoon, Lumos was up a slight 0.85 per cent to trade at 86 cents per share at 2:11 pm AEDT.

LDX by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…